Mass spectrometric analysis of the HIV-1 integrase-pyridoxal 5′-phosphate complex reveals a new binding site for a nucleotide inhibitor

Abstract

HIV-1 integrase (IN) is an important target for designing new antiviral therapies. Screening of potential inhibitors using recombinant IN-based assays lias revealed a number of promising leads including nucleotide analogs such as pyridoxal 5′-phosphate (PLP). Certain PLP derivatives were shown to also exhibit antiviral activities in cell-based assays. To identify an inhibitory binding site of PLP to IN, we used the intrinsic chemical property of this compound to form a Schiff base with a primary amine in the protein at the nucleotide binding site. The amino acid affected was then revealed by mass spectrometric analysis of the proteolytic peptide fragments of IN. We found that an IC50 concentration (15 μM) of PLP modified a single IN residue, Lys244, located in the C-terminal domain. In fact, we observed a correlation between interaction of PLP with Lys244 and the compound's ability to impair formation of the IN-DNA complex. Site-directed mutagenesis studies confirmed an essential role of Lys244 for catalytic activities of recombinant IN and viral replication. Molecular modeling revealed that Lys244 together with several other DNA binding residues provides a plausible pocket for a nucleotide inhibitor-binding site. To our knowledge, this is the first report indicating that a small molecule inhibitor can impair IN activity through its binding to the protein C terminus. At the same time, our findings highlight the importance of structural analysis of the full-length protein.